Cardiovascular side-effects of modern cancer therapy

Circulation Journal

Volumn 74, Issue 9, 2010, Pages 1779-1786

  Minami, Manabu ^a   Matsumoto, Shigemi ^a   Horiuchi, Hisanori ^b  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

Cancer; Cardioncology; Cardiotoxicity; Chemotherapy

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; DOXORUBICINOL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; IDARUBICIN; IMATINIB; LAPATINIB; PACLITAXEL; RITUXIMAB; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; ACUTE HEART INFARCTION; ADJUVANT THERAPY; ADVANCED CANCER; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; AUTOIMMUNE DISEASE; BRAIN DISEASE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BREAST CANCER; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DIASTOLIC DYSFUNCTION; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM PERFORATION; DOPPLER ECHOCARDIOGRAPHY; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART BLOCK; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEMORRHAGIC CYSTITIS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOTENSION; INTESTINE ISCHEMIA; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKEMIA; LUNG CANCER; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE CYCLE TREATMENT; MYOCARDITIS; NEPHROTOXICITY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OTOTOXICITY; OVARY CANCER; PATIENT MONITORING; PERICARDITIS; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PHARYNX CANCER; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; SINUS BRADYCARDIA; SKIN CANCER; SOFT TISSUE TUMOR; SOLID TUMOR; SUPRAVENTRICULAR TACHYCARDIA; SYNCOPE; THROMBOEMBOLISM; TREATMENT RESPONSE; UROGENITAL TRACT CANCER;

ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; NEOPLASMS;

EID: 77956131242     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0632     Document Type: Review

References (61)

1. Cardinale D, Colombo A, Cipolla CM. Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy. Curr Treat Options Cardiovasc Med 2008; 10: 486-495.
2. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185-229.
3. Morimoto T, Fujita M, Kawamura T, Sunagawa Y, Takaya T, Wada H, et al. Myocardial regulation of p300 and p53 by doxorubicin involves ubiquitin pathways. Circ J 2008; 72: 1506-1511.
4. Su YW, Liang C, Jin HF, Tang XY, Han W, Chai LJ, et al. Hydrogen sulfide regulates cardiac function and structure in adriamycininduced cardiomyopathy. Circ J 2009; 73: 741-749.
5. Takaya T, Ono K, Kawamura T, Takanabe R, Kaichi S, Morimoto T, et al. MicroRNA-1 and microRNA-133 in spontaneous myocardial differentiation of mouse embryonic stem cells. Circ J 2009; 73: 1492-1497.
6. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47-58.
7. Ikegami E, Fukazawa R, Kanbe M, Watanabe M, Abe M, Watanabe M, et al. Edaravone, a potent free radical scavenger, prevents anthracycline- induced myocardial cell death. Circ J 2007; 71: 1815-1820.
8. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicininduced cardiotoxicity. Circulation 2005; 112: 3754-3762.
9. Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 1981; 102: 709-718.
10. Tassan-Mangina S, Codorean D, Metivier M, Costa B, Himberlin C, Jouannaud C, et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: Early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006; 7: 141-146.
11. Monsuez JJ, Charniot JC, Vignat N, Artigou JY. Cardiac side-effects of cancer chemotherapy. Int J Cardiol 2010 [E-pub ahead of print].
12. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672-1677.
13. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-815.
14. Larsen RL, Jakacki RI, Vetter VL, Meadows AT, Silber JH, Barber G. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 1992; 70: 73-77.
15. Huang C, Zhang X, Ramil JM, Rikka S, Kim L, Lee Y, et al. Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stressinduced myocardial injury in adult mice. Circulation 2010; 121: 675-683.
16. Arbuck SG, Strauss H, Rowinsky E, Christian M, Suffness M, Adams J, et al. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr 1993; 117-130.
17. Salvatorelli E, Menna P, Cascegna S, Liberi G, Calafiore AM, Gianni L, et al. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies. J Pharmacol Exp Ther 2006; 318: 424-433.
18. de Forni M, Malet-Martino MC, Jaillais P, Shubinski RE, Bachaud JM, Lemaire L, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: A prospective clinical study. J Clin Oncol 1992; 10: 1795-1801.
19. Collins C, Weiden PL. Cardiotoxicity of 5-fluorouracil. Cancer Treat Rep 1987; 71: 733-736.
20. Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006; 58: 487-493.
21. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758-763.
22. Taniguchi I. Clinical significance of cyclophosphamide-induced cardiotoxicity. Intern Med 2005; 44: 89-90.
23. Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18: 1725-1732.
24. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
25. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
26. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-1221.
27. Sengupta PP, Northfelt DW, Gentile F, Zamorano JL, Khandheria BK. Trastuzumab-induced cardiotoxicity: Heart failure at the crossroads. Mayo Clin Proc 2008; 83: 197-203.
28. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
29. Ferrari R, Ceconi C, Campo G, Cangiano E, Cavazza C, Secchiero P, et al. Mechanisms of remodelling. Circ J 2009; 73: 1973-1982.
30. Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA, et al. Neuregulins promote survival and growth of cardiac myocytes: Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998; 273: 10261-10269.
31. Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R, et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 1995; 378: 390-394.
32. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995; 378: 394-398.
33. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature 1995; 378: 386-390.
34. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 8: 459-465.
35. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007; 18: 977-984.
36. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25: 3859-3865.
37. Bengala C, Zamagni C, Pedrazzoli P, Matteucci P, Ballestrero A, Da Prada G, et al. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: A retrospective study. Br J Cancer 2006; 94: 1016-1020.
38. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23: 7820-7826.
39. Machiels JP, Sempoux C, Scalliet P, Coche JC, Humblet Y, Van Cutsem E, et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol 2007; 18: 738-744.
40. Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006; 24: 1072-1078.
41. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008; 83: 679-686.
42. Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: What are the important clinical markers to target? Oncologist 2010; 15: 130-141.
43. Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, et al. Management of bevacizumab-associated bowel perforation: A case series and review of the literature. Ann Oncol 2008; 19: 577-582.
44. Yardley DA. Integrating bevacizumab into the treatment of patients with early-stage breast cancer: Focus on cardiac safety. Clin Breast Cancer 2010; 10: 119-129.
45. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-2019.
46. Di Lorenzo G, Autorino R, Bruni G, Carteni G, Ricevuto E, Tudini M, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: A multicenter analysis. Ann Oncol 2009; 20: 1535-1542.
47. Wong MK, Jarkowski A. Response to sorafenib after sunitinibinduced acute heart failure in a patient with metastatic renal cell carcinoma: Case report and review of the literature. Pharmacotherapy 2009; 29: 473-478.
48. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncol 2008; 9: 117-123.
49. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908-916.
50. Turrisi G, Montagnani F, Grotti S, Marinozzi C, Bolognese L, Fiorentini G. Congestive heart failure during imatinib mesylate treatment. Int J Cardiol 2009 [E-pub ahead of print].
51. Kilickap S, Yavuz B, Aksoy S, Sahiner L, Dincer M, Harputluoglu H, et al. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma. Med Oncol 2008; 25: 437-442.
52. Cardinale D, Sandri MT, Martinoni A, Borghini E, Civelli M, Lamantia G, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002; 13: 710-715.
53. Koh E, Nakamura T, Takahashi H. Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circ J 2004; 68: 163-167.
54. Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, et al. N-terminal pro-B-type natriuretic peptide after highdose chemotherapy: A marker predictive of cardiac dysfunction? Clin Chem 2005; 51: 1405-1410.
55. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010; 55: 213-220.
56. Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: Updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009; 100: 684-692.
57. Hara K, Kadowaki T. How controlling of hypertension might matter. Circ J 2009; 73: 2208-2209.
58. Pande A, Lombardo J, Spangenthal E, Javle M. Hypertension secondary to anti-angiogenic therapy: Experience with bevacizumab. Anticancer Res 2007; 27: 3465-3470.
59. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94: 25-36.
60. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997; 15: 1318-1332.
61. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355: 1572-1582.